Harry Palmin has a successful track record of building, financing and operating a public / private life sciences company over 15 years, twice taking a company public.  He is a Venture Partner at Extera Partners, LLC and is currently serving as President and CEO and a Director at Acer Therapeutics Inc., an Extera Accelerator company. Acer is developing the first pharmaceutical therapy for patients with Maple Syrup Urine Disease (MSUD).  Harry previously served as President and a Director at Novelos Therapeutics, Inc. from 1998 and Novelos’ CEO from 2005 to October 2013; from 1998 to 2005, he also served as Novelos’ acting CFO.  He built Novelos from a concept into a $500 million (peak market capitalization) public oncology and infectious disease development company that completed a pivotal Phase 3 lung cancer trial.  Harry then rebuilt Novelos as a public company around a cancer-targeted delivery platform with 3 lead compounds.  He raised $98 million in pursuit of Novelos’ drug development and commercial objectives; and recruited, led and managed executive teams.  Harry oversaw 10 clinical studies in oncology and infectious diseases.  From 1996 to 1998, Harry was a Vice President at Lehman Brothers and from 1993 to 1996, he was an Associate at Morgan Stanley & Co.  Harry earned a B.A. in economics and business, magna cum laude, and a M.A. in international economics and finance from the International Business School at Brandeis University.  He has also studied at the London School of Economics and the Copenhagen Business School.